

Scientific Horizons and Opportunities in Pharmacogenomics Research
Organized by the Pharmacogenomics Research Network (PGRN)

Wednesday, March 9, 2016
San Diego, CA

Time	Duration	Topic
7:00 AM	60 min	Breakfast
8:00 AM	15 min	Overview of the PGRN Transition Rochelle M. Long, Ph.D. (National Institutes of Health)

Emerging Horizons in Pharmacogenomics Research
Moderator: Mary V. Relling, Pharm.D. (St. Jude Children's Research Hospital)

8:15 AM	30 min	Center for Precision Medicine in Leukemia: Genome Variants Influencing <i>de novo</i> and Acquired Resistance to Antileukemic Agents William Evans, Pharm.D. (St. Jude Children's Research Hospital)
8:45 AM	30 min	The Vanderbilt P50 Center: New Approaches to Evaluating the Genetics of Adverse Drug Reactions Elizabeth J. Phillips, M.D. (Vanderbilt University)
9:15 AM	30 min	Systems Pharmacogenomics of Statin Therapy Research Ronald M. Krauss, M.D. (Children's Hospital Oakland Institute)
9:45 AM	30 min	Improving Clinical Outcomes Through Pharmacogenomics Julie A. Johnson, Pharm.D. (University of Florida)
10:15 AM	15 min	Break

Pharmacogenomics Resources of the PGRN
Moderator: Sook Wah Yee, Ph.D. (University of California San Francisco)

10:30 AM	25 min	Warfarin Pharmacogenomics in Alaskan Natives: Focus on Novel Pharmacogene Variant Function Allan E. Rettie, Ph.D. (University of Washington)
10:55 AM	25 min	Clinical Pharmacogenetics Implementation Consortium

		Mary V. Relling, Pharm.D. (St. Jude Children's Research Hospital)
11:20 AM	25 min	PharmGKB: Pharmacogenomics Knowledge for Precision Medicine Teri E. Klein, Ph.D. (Stanford University)
11:45 AM	30 min	Lunch

Panel Discussion on Partnership Opportunities
Moderators: Kathleen M. Giacomini, Ph.D. (University of California San Francisco) and Rachel F. Tyndale, Ph.D. (University of Toronto)
12:15 PM to 1:30 PM

12:15 PM	10 min	Introduction by Moderator Kathleen M. Giacomini, Ph.D. (University of California San Francisco)
12:25 PM	10 min	PGRN Website Megan Riel-Mehan, Ph.D. (University of California San Francisco)

Panelists

Alan R. Shuldiner, M.D. Center	Vice President and Co-Head, Regeneron Genetics
Michael A. Pacanowski, Pharm.D	Associate Director for Genomics and Targeted Therapy, U.S. Food and Drug Administration
Joshua C. Denny, M.D. Medicine	Associate Professor, Vanderbilt University School of
Richard M. Weinshilboum, M.D.	Professor of Medicine, Mayo Clinic

1:30 PM	30 min	Pharmacogenetic Implementation Initiatives in Europe Ron H.N. van Schaik, Ph.D. (Erasmus University) Jesse J. Swen, Pharm.D., Ph.D. (Leiden University)
---------	--------	--

Session Description:

The field of pharmacogenomics received considerable attention when President Obama launched the Precision Medicine Initiative earlier this year. The Pharmacogenomics Research Network (PGRN) is bringing together scientists who study the interactions between genes and drug responses. This session, organized by the PGRN and open to all ASCPT attendees, is intended to present new research horizons in pharmacogenomics and precision medicine. The session includes an interactive panel discussion with different stakeholders who will describe emerging opportunities for research partnerships in pharmacogenomics. This special session is intended for a diverse range of scientists across multiple sectors who are interested in learning about the latest research in pharmacogenomics and precision medicine. Importantly,

the session is intended to present new opportunities for collaborative research and access to innovative resources to advance research in basic and translational pharmacogenomics.